Cite
Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)
MLA
AeRang Kim, et al. “Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).” Sarcoma, vol. 2020, Jan. 2020. EBSCOhost, https://doi.org/10.1155/2020/5784876.
APA
AeRang Kim, Yao Lu, Scott H. Okuno, Denise Reinke, Ophélia Maertens, John Perentesis, Mitali Basu, Pamela L. Wolters, Thomas De Raedt, Sant Chawla, Rashmi Chugh, Brian A. Van Tine, Geraldine O’Sullivan, Alice Chen, Karen Cichowski, & Brigitte C. Widemann. (2020). Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma, 2020. https://doi.org/10.1155/2020/5784876
Chicago
AeRang Kim, Yao Lu, Scott H. Okuno, Denise Reinke, Ophélia Maertens, John Perentesis, Mitali Basu, et al. 2020. “Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).” Sarcoma 2020 (January). doi:10.1155/2020/5784876.